Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 257.46B +7.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.09 |
| Forward PE | 16.04 |
| Dividend | 9.80 (3.04%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 778,976 |
| Average Volume | 1,224,739 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| RSI | 30.66 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details. ... Full story available on Benzinga.com
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
C4 Therapeutics Enters Collaboration Agreement With Roche
(RTTNews) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate or DAC, modality. C4 Therapeu...
3 Dividend Stocks for April 2026
#DividendStocks2026 #DividendStocks #BestDividendStocks These wide- and narrow-moat companies recently raised their dividends. Subscribe to the Morningstar DividendInvestor newsletter.
HNL Lab Medicine Celebrates Preferred Partnership With Roche Diagnostics
ALLENTOWN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine today announced a preferred partnership with Roche Diagnostics.
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices
New tax will hit branded drugs and active ingredients while exempting generics for at least one year
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.
Top Stock Reports for Roche, AT&T & Amgen
Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.
Roche Announces Launch Of Cobas MPX-E Assay
(RTTNews) - Roche (RO.SW, ROG.SW) announced that the cobas MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus and Hepatitis C, B, and E virus...
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
Basel, 30 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus ...
Vector Institute Extends Collaboration With Roche
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Today, the Vector Institute announced the renewal of its collaboration with Roche through 2030, extending a connection that has advanced artificial intellig...
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis , and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident a...
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Basel, 23 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the inauguration of the new research home for the Institute of Human Biology. The opening marks a significant milestone in Roc...
Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says
The company discontinued developing emugrobart after two studies showed the drug didn't achieve intended outcomes.
Roche (RHHBY) Continues Obesity Trials Despite Neuromuscular Setbacks
Roche (RHHBY) Continues Obesity Trials Despite Neuromuscular Setbacks
Roche Bets Splits in Obesity Market Will Open Door to New Entrants
EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the likes of Eli Lilly and Novo Nordisk.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
Roche's Ionify® steroid assays join its Vitamin D Total test as the latest mass spectrometry tests to receive CLIA 'moderate complexity' classification. The expanded steroid menu brings the sensitivit...
Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies
Mankind Pharma Limited has announced its acquisition of the Rivotril brand from Roche for the Indian market. This acquisition grants Mankind Pharma exclusive rights to manufacture, market, and distrib...
Roche Expands AI Power With NVIDIA Blackwell GPUs
(RTTNews) - Roche announced a major expansion of its global AI infrastructure, unveiling the pharmaceutical industry's largest hybrid-cloud AI factory. With the addition of 2,176 NVIDIA Blackwell GPUs...
Roche (RHHBY) Expands AI Capabilities with Nvidia Partnership
Roche (RHHBY) Expands AI Capabilities with Nvidia Partnership